State coverage
Tennessee
Medicaid, for obesity: Covers with conditions. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Covered since August 1, 2025. Wegovy and Zepbound are preferred; older appetite drugs need no approval.
- Appeal deadline
- Not published — both TennCare rule chapters were obtained in full, along with the pharmacy notices and the PA forms, and none of them states a filing window for a pharmacy denial. Federal ceiling: no more than 90 days.
- Date read
- September 2026
Tennessee added this benefit rather than removing it, and it did so with an unusually open door at the low-cost end. The older appetite and absorption drugs are preferred and, on the state's own form, need no prior authorization at all — a quantity limit and nothing else. That is rare enough to be worth stating plainly, because most states on this site gate every anti-obesity drug behind a form.
The GLP-1 drugs are a different tier. Two are preferred and both need approval; two more sit in the non-preferred column and need a documented failure of a preferred product before they will be considered. So the structure rewards starting cheap, and the paperwork burden rises with the price of the drug.
One feature has no equivalent on any other state page here. Tennessee's three managed care plans each run wraparound programs for members taking these drugs — dietitian counseling, behavioral health support, health coaching — and the state published a notice naming them. Whatever else that is, it is a state treating the prescription as one part of a program rather than the whole of it.
We are not printing a Tennessee filing deadline. We searched the two TennCare rule chapters obtained in this session — one of about 270,000 characters and one of about 51,000 — plus the pharmacy provider notices and the prior authorization forms, and none of them states a window for appealing a pharmacy denial. The rule chapters mention appeals only in passing, and the deadline is not in them. A document we have not read is not a number we will print. The federal ceiling that applies everywhere is on the procedures page, and your own notice carries the number that binds you.
What we could verify for Tennessee
Tennessee started covering these drugs on a dated notice, for adults and children alike. Its provider notice states: "Effective August 1, 2025, medications for obesity management will be covered for both adults (ages 21 and over) and children per medication label subject to interim prior authorization (PA) criteria and quantity limits." The pharmacy benefit is administered for TennCare by OptumRx, whose support center the notice directs providers to.
State of Tennessee, Division of TennCare (Provider Notice, Obesity Management Agents), effective August 2025 · source
A whole tier of anti-obesity drugs carries no prior authorization requirement in Tennessee. The notice lists as "preferred without PA" benzphetamine, diethylpropion, Lomaira, orlistat, phendimetrazine, phentermine and phentermine/topiramate, each with a quantity limit. The state's own prior authorization form repeats this, heading that block "Appetite and Absorption Agents (No PA Required*)" and adding Xenical to it. The asterisk carries a caution: "These agents are intended for short-term obesity management; and benefits should outweigh risks. Abrupt cessation should be avoided. Tapering is recommended."
State of Tennessee, Division of TennCare (Weight Management Agents Prior Authorization Form, revision date 08/2026), effective August 2026 · source
The GLP-1 tier is split preferred against non-preferred, and the split decides how much you have to prove. The form's "GLP-1 Weight Management Agents" table lists as preferred "Wegovy® injection" and "Zepbound® single dose prefilled pen," both flagged for prior authorization and a quantity limit, against non-preferred "liraglutide (weight management)" and "Saxenda®," flagged the same way. For the non-preferred pair the form asks whether "the patient failed, had an adverse event or intolerance to a preferred product," and for liraglutide specifically whether the patient failed or could not tolerate Saxenda.
State of Tennessee, Division of TennCare (Weight Management Agents Prior Authorization Form, revision date 08/2026), effective August 2026 · source
The entry test for a GLP-1 is a body mass index floor with a comorbidity alternative, and it is age-banded. The form asks for records supporting one of: "For patients < 18 years of age and weight > 95th percentile standardized for age and sex" or, for patients over 18, "Initial BMI > 30 kg/m2" or "BMI > 27 kg/m2 AND patient has a weight related comorbidity (e.g., hypertension, dyslipidemia, diabetes, coronary heart disease, MASH/NASH, obstructive sleep apnea)." It also requires the prescriber to attest that the patient "is participating in complementary nutritional and lifestyle changes," and asks whether the drug will be combined with other obesity medications or with another GLP-1 receptor agonist, and about any personal or immediate family history of medullary thyroid carcinoma or MEN2.
State of Tennessee, Division of TennCare (Weight Management Agents Prior Authorization Form, revision date 08/2026), effective August 2026 · source
Tennessee wraps the prescription in plan-run services and published a notice saying so. "Each of TennCare's three Managed Care Organizations (MCOs) are offering wraparound services to support patients utilizing GLP-1 Agonists for weight management. The MCOs services include nutrition/dietician counseling, behavioral health support, case management/health coaching, and digital engagement." The three named are BlueCare, UnitedHealthcare Community Plan and Wellpoint. One of them describes an "Obesity Model of Care" developed "to support TennCare members with obesity, particularly those using incretin-based therapies, by pairing pharmacotherapy with evidence-based wraparound supports." Which services you can reach depends on which plan you are in.
State of Tennessee, Division of TennCare (Provider Notice, Weight Management MCO Wraparound Services), effective August 2026 · source
The preferred drug list is still being rebuilt class by class, so a drug's status is a moving target rather than a settled fact. TennCare's August 2026 notice states: "TennCare is continuing the process of reviewing all covered drug classes. Changes to the PDL occur as new classes are reviewed, and previously reviewed classes are revisited. As a result of these changes, some medications your patients are taking may be considered non-preferred agents in the future." It directs readers to the OptumRx TennCare site for the clinical criteria behind each class.
State of Tennessee, Division of TennCare (Provider Notice, Preferred Drug List effective August 1, 2026), effective August 2026 · source
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
- CoreAge RxAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
- OakFlat price across doses, free shipping with supplies.
- Care Bare RxNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
- Gala HealthAll doses one price, but the advertised rate needs a yearly subscription.
- Synergy RxProviders licensed in your state; publishes no GLP-1 price before the consult.
- Breeze MedsServes all 50 states; publishes a starting price only.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Where this comes from
- State of Tennessee, Division of TennCare (Provider Notice, Obesity Management Agents), effective August 2025 — contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenn
- State of Tennessee, Division of TennCare (Weight Management Agents Prior Authorization Form, revision date 08/2026), effective August 2026 — contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenn
- State of Tennessee, Division of TennCare (Provider Notice, Weight Management MCO Wraparound Services), effective August 2026 — contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenn
- State of Tennessee, Division of TennCare (Provider Notice, Preferred Drug List effective August 1, 2026), effective August 2026 — contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenn
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.